TerraPower Isotopes (TPI), a subsidiary of Bill Gates-founded nuclear innovation company TerraPower, broke ground on 6 May 2026 on the Bellwether Laboratory, its flagship actinium-225 (Ac-225) manufacturing facility in South Philadelphia’s Bellwether District. The 250,000-square-foot current Good Manufacturing Practices (cGMP) facility represents a $450 million private investment and is being developed as a build-to-suit lease arrangement with Philadelphia real estate developer HRP Group on the 1,300-acre site of the former Philadelphia Energy Solutions refinery. Combined with TPI’s existing and expanding operations in Everett, Washington, the Bellwether Laboratory is designed to increase global Ac-225 production capacity twentyfold, positioning TPI as the premier global distributor of the isotope. Construction jobs are estimated at approximately 500, with the facility projected to support roughly 225 full-time positions once operational. Production of cGMP-grade Ac-225 is scheduled to begin in mid-to-late 2029. The Pennsylvania state government is backing the project with a $10 million grant, and the Bellwether District’s Keystone Opportunity Zone designation provides TPI with significant tax benefits running through 2043. TPI selected the Philadelphia site following evaluation of more than 350 potential locations across eight metropolitan areas, ultimately citing the region’s dense pharmaceutical ecosystem, academic talent pipeline, and strong government support as deciding factors.
Philadelphia Cements Its Place at the Heart of the Radiopharmaceutical Revolution
The Bellwether Laboratory arrives at a pivotal moment for the targeted alpha therapy sector, where demand for Ac-225 has long outpaced supply, constraining clinical development programmes across dozens of pharmaceutical companies worldwide. Ac-225 is produced in extremely limited quantities from weapons-grade uranium and has historically been accessible only through a handful of government-affiliated sources, including Oak Ridge National Laboratory in Tennessee and Russia’s Rosatom. TPI’s facility fundamentally alters that picture. Philadelphia is not a newcomer to nuclear medicine, but the Bellwether Laboratory takes the city into a different league entirely. The broader region already hosts operations from Lantheus Holdings, which manufactures PSMA-targeted radiopharmaceuticals for prostate cancer, and Bristol Myers Squibb, whose radiopharmaceutical pipeline has expanded aggressively through recent acquisitions. The Bellwether District itself has attracted a growing cluster of life sciences and advanced manufacturing tenants, drawing comparisons to the way South San Francisco evolved around Genentech into one of the world’s premier biotech corridors. That Philadelphia has secured the world’s largest Ac-225 plant is a meaningful signal to drug developers that the East Coast now offers a credible, large-scale supply chain for the isotope. This rapid scaling of nuclear-linked infrastructure also parallels developments in the energy sector, where major tech companies are beginning to position nuclear power as a strategic enabler of future compute demand, including Amazon’s recent move highlighted in its accelerating bet on small modular reactors (SMRs). Targeted alpha therapy works by coupling radioactive isotopes with targeting molecules to deliver localised radiation doses directly to tumour cells, offering precision that conventional radiotherapy cannot match, and clinical programmes for prostate, breast, and neuroendocrine cancers are advancing rapidly on the back of early results.
Project Fact Sheet
- Project Name: Bellwether Laboratory, TerraPower Isotopes
- Location: Bellwether District, South Philadelphia, Pennsylvania, USA
- Project Value: US$450 million
- Client/Owner: TerraPower Isotopes (TPI), a subsidiary of TerraPower
- Developer/Landlord: HRP Group
- Facility Size: 250,000 square feet
- Key Product: Actinium-225 (Ac-225) for targeted alpha cancer therapies
- Facility Standard: current Good Manufacturing Practices (cGMP)
- Procurement Model: Build-to-suit lease
- Construction Start: May 2026
- Expected Completion / Production Start: Mid-to-late 2029
- Full-Time Jobs Created: Approximately 225 permanent roles
- Construction Jobs: Approximately 500
- Strategic Impact: Twentyfold increase in global Ac-225 supply capacity; positions TPI as premier global distributor
Project Team
- Client/Owner: TerraPower Isotopes (TPI) / TerraPower (parent company, founded by Bill Gates)
- Developer and Facility Builder: HRP Group, Philadelphia
- Government Sponsor: Commonwealth of Pennsylvania, represented by Governor Josh Shapiro’s administration; $10 million grant through the Pennsylvania Department of Community and Economic Development
- Regulatory Framework: US Nuclear Regulatory Commission (NRC); US Food and Drug Administration (FDA) cGMP compliance
- Tax Incentive Authority: Pennsylvania Keystone Opportunity Zone Programme (benefits through 2043)
- Likely General Contractor: Expected to be drawn from firms with life sciences and cleanroom manufacturing experience active in the mid-Atlantic region, such as Barton Malow, Gilbane Building Company, or Turner Construction
- Likely Engineering and Validation: Firms specialising in nuclear-grade pharmaceutical facilities such as CRB Group or Jacobs Engineering are likely candidates for process design and cGMP validation work
